National Institutes of Health, US Department of Health and Human Services, Bethesda, MD 20892-3719, USA.
Neuron. 2012 Jun 7;74(5):773-6. doi: 10.1016/j.neuron.2012.05.004.
Despite the need for more effective treatments for psychiatric disorders, development of new medications has stalled. Here we discuss the promise of personalized medicine in developing more efficacious and individualized pharmacotherapies that take into account genetic variation and target groups of patients who share biology, not just symptoms.
尽管我们需要更有效的精神疾病治疗方法，但新药物的研发已经停滞不前。在这里，我们讨论了个性化医学在开发更有效和个体化药物治疗方面的前景，这些治疗方法考虑了遗传变异，并针对具有共同生物学特征而非仅仅是症状的患者群体。
